Wayne Tam

List of Publications by Year in descending order

103 papers	9,392 citations	117625 34 h-index	56724 83 g-index
107 all docs	107 docs citations	107 times ranked	15015 citing authors

#	Article	IF	Citations
1	Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas. Blood, 2022, 139, 73-86.	1.4	13
2	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 972-983.	7.0	22
3	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer Journal, 2022, 12, 25.	6.2	7
4	Mutation landscape, clonal evolution pattern, and potential pathogenic pathways in B-lymphoblastic transformation of follicular lymphoma. Leukemia, 2021, 35, 1203-1208.	7.2	8
5	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology, 2021, 34, 20-31.	5.5	9
6	T-cell neoplasms in the spleen. Seminars in Diagnostic Pathology, 2021, 38, 135-143.	1.5	0
7	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Molecular Cancer Research, 2021, 19, 249-260.	3.4	20
8	GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leukemia Research, 2021, 100, 106495.	0.8	2
9	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology, 2021, 34, 1358-1366.	5.5	8
10	Myeloid, mast cell, histiocytic and dendritic cell neoplasms and proliferations involving the spleen. Seminars in Diagnostic Pathology, 2021, 38, 144-153.	1.5	0
11	In Vivo and Ex Vivo Patientâ€Derived Tumor Xenograft Models of Lymphoma for Drug Discovery. Current Protocols, 2021, 1, e96.	2.9	1
12	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 44.	5.4	20
13	Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685.	5.5	21
14	Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Frontiers in Oncology, 2021, 11, 701318.	2.8	10
15	Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. ELife, 2021, 10, .	6.0	19
16	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Science Alliance, 2021, 4, e202000955.	2.8	56
17	Meet the Associate Editor. MicroRNA (Shariqah, United Arab Emirates), 2021, 10, 2-2.	1.2	0
18	Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents. Blood, 2021, 138, 2406-2406.	1.4	1

#	Article	IF	Citations
19	Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. Blood, 2021, 138, 2395-2395.	1.4	1
20	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. Blood, 2021, 138, 704-704.	1.4	0
21	Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. Scientific Reports, 2020, 10, 13094.	3.3	8
22	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Advances, 2020, 4, 3391-3404.	5.2	22
23	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. Journal of Hematology and Oncology, 2020, 13, 148.	17.0	27
24	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. Haematologica, 2020, 105, 2432-2439.	3.5	16
25	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. Cancers, 2020, 12, 1603.	3.7	11
26	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. Nature Cancer, 2020, 1, 653-664.	13.2	35
27	Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a â€œgrey zoneâ€•combination of myelodysplastic and myeloproliferative features?. Haematologica, 2020, 105, e276-e279.	3.5	14
28	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature, 2019, 571, 355-360.	27.8	206
29	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
30	Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse. Blood Cancer Journal, 2019, 9, 69.	6.2	4
31	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Modern Pathology, 2019, 32, 741-754.	5.5	39
32	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 2838-2840.	1.3	24
33	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research, 2019, 7, 644-657.	3.4	106
34	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Modern Pathology, 2019, 32, 490-498.	5.5	50
35	Assessment of the Utility of Cytology and Flow Cytometry of Cerebrospinal Fluid Samples in Clinical Practice. Acta Cytologica, 2018, 62, 130-136.	1.3	5
36	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood, 2018, 131, 1415-1424.	1.4	160

#	Article	IF	Citations
37	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discovery, 2018, 8, 1632-1653.	9.4	120
38	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer Research, 2018, 78, 3413-3420.	0.9	31
39	Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. Journal of Hematology and Oncology, 2018, 11, 105.	17.0	26
40	A multimodality workâ€up of patients with Hypereosinophilia. American Journal of Hematology, 2018, 93, 1337-1346.	4.1	14
41	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discovery, 2017, 7, 506-521.	9.4	43
42	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360.	3.5	62
43	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2017, 187, 1700-1716.	3.8	39
44	The effect of initial molecular profile on response to recombinant interferonâ€Î± (rIFNÎ±) treatment in early myelofibrosis. Cancer, 2017, 123, 2680-2687.	4.1	48
45	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq1 1 0.784314 rgBT /Overlock 10 chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	5.5	52
46	Dysregulation of Blimp1 transcriptional repressor unleashes p130Cas/ErbB2 breast cancer invasion. Scientific Reports, 2017, 7, 1145.	3.3	17
47	An intrasinusoidal extracavitary variant of primary effusion lymphoma. Blood, 2017, 130, 836-836.	1.4	4
48	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	9.4	218
49	Pure Erythroid Leukemia Mimicking Ewing Sarcoma/Primitive Neuroectodermal Tumor in an Infant. Pediatric Blood and Cancer, 2016, 63, 935-937.	1.5	7
50	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	5.5	104
51	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell, 2016, 167, 405-418.e13.	28.9	204
52	Cutaneous myeloid dendritic cell dyscrasia: A cutaneous clonal monocytosis associated with chronic myeloproliferative disorders and peripheral blood monocytosis. Annals of Diagnostic Pathology, 2016, 25, 85-91.	1.3	6
53	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. Npj Genomic Medicine, 2016, 1, .	3.8	68
54	The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNÎ±) Treatment in Early Myelofibrosis. Blood, 2016, 128, 944-944.	1.4	3

#	Article	IF	Citations
55	Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget, 2016, 7, 3520-3532.	1.8	26
56	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. Blood, 2016, 128, 735-735.	1.4	0
57	The tumor virus landscape of AIDS-related lymphomas. Blood, 2015, 125, e14-e22.	1.4	67
58	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood, 2015, 125, 1061-1072.	1.4	281
59	VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma. Journal of Visualized Experiments, 2015, , e53215.	0.3	7
60	Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. Human Pathology, 2015, 46, 260-271.	2.0	63
61	Cyclin D1â€“Positive Diffuse Large B-Cell Lymphoma With IGH-CCND1 Translocation and BCL6 Rearrangement. American Journal of Clinical Pathology, 2015, 143, 288-299.	0.7	21
62	Massive splenic hamartoma with bizarre stromal cells. International Journal of Hematology, 2015, 101, 315-316.	1.6	4
63	Cryptococcosis in bone marrow following treatment for Hodgkin lymphoma. International Journal of Hematology, 2015, 101, 211-212.	1.6	1
64	Primary Cutaneous Follicle Center Lymphoma Associated With an Extracutaneous Dissemination: A Cytogenetic Finding of Potential Prognostic Value. American Journal of Clinical Pathology, 2015, 144, 805-810.	0.7	9
65	Epigenomic evolution in diffuse large B-cell lymphomas. Nature Communications, 2015, 6, 6921.	12.8	111
66	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nature Medicine, 2015, 21, 1199-1208.	30.7	359
67	Angiocrine Factors Deployed by Tumor Vascular Niche Induce B Cell Lymphoma Invasiveness and Chemoresistance. Cancer Cell, 2014, 25, 350-365.	16.8	203
68	Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biology, 2014, 15, 432.	8.8	71
69	EBV Microrna Mir-BHRF1-2 Targets PRDM1/Blimp1: Potential Role in EBV Lymphomagenesis. Blood, 2014, 124, 3547-3547.	1.4	0
70	Aberrantly sustained PAX5 expression in plasma cell differentiation is a frequent feature in lymphoplasmacytic lymphoma but not marginal zone lymphoma in bone marrow. Journal of Hematopathology, 2013, 6, 169-177.	0.4	0
71	Diffuse variant of lymphocyte-predominant Hodgkin lymphoma: a diagnostic challenge. Journal of Hematopathology, 2013, 6, 145-150.	0.4	0
72	Inactivation Of BANK1 By a Novel IGH-Associated Translocation and 5â€™ Hypermethylation In B-Cell Lymphomas. Blood, 2013, 122, 2497-2497.	1.4	1

#	Article	IF	Citations
73	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. Blood, 2013, 122, 634-634.	1.4	2
74	Deep Sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated With Relapse In B Cell Lymphomas. Blood, 2013, 122, 79-79.	1.4	1
75	IL10 Receptor a Is a Novel Therapeutic Target That Is Epigenetically Disregulated in Low Grade Lymphomas with Plasmacytic Differentiation.. Blood, 2012, 120, 2383-2383.	1.4	0
76	Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing. Blood, 2012, 120, 899-899.	1.4	0
77	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	1.4	3
78	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. Blood, 2011, 118, 1617-1617.	1.4	0
79	Promoter and Exon 1 Hypermethylation of the Tumor Suppressor Gene PRDM1/Blimp-1 indicates Its Pathogenetic Role in EBV-Positive Burkitt Lymphoma,. Blood, 2011, 118, 3471-3471.	1.4	0
80	Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation. Blood, 2011, 118, 1579-1579.	1.4	7
81	MicroRNAs of the immune system. Annals of the New York Academy of Sciences, 2010, 1183, 183-194.	3.8	149
82	Epigenetic Down-Regulation of the Tumor Suppressor Gene PRDM1/Blimp-1 in Diffuse Large B Cell Lymphomas. American Journal of Pathology, 2010, 177, 1470-1479.	3.8	56
83	TNFAIP3 (A20) Genetic Alterations In EBV Associated AIDS Related Lymphomas. Blood, 2010, 116, 802-802.	1.4	0
84	MicroRNA-155 Modulates Transforming Growth Factor-Î² Signaling In Chronic Lymphocytic Leukemia through Targeting of Casein Kinase Î³ Isoform 2. Blood, 2010, 116, 3584-3584.	1.4	0
85	Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis.. Blood, 2010, 116, 3853-3853.	1.4	53
86	Reticuloendotheliosis Virus Strain T Induces miR-155, Which Targets JARID2 and Promotes Cell Survival. Journal of Virology, 2009, 83, 12009-12017.	3.4	95
87	Micro-classifying diffuse large B-cell lymphomas. Blood, 2009, 113, 6506-6507.	1.4	1
88	ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 4686-4686.	1.4	0
89	MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg Cells: A Potential Pathogenetic Lesion in Hodgkin Lymphomas. American Journal of Pathology, 2008, 173, 242-252.	3.8	154
90	The Emergent Role of MicroRNAs in Molecular Diagnostics of Cancer. Journal of Molecular Diagnostics, 2008, 10, 411-414.	2.8	22

#	Article	IF	Citations
91	Significance of PRDM1Î² expression as a prognostic marker in diffuse large B-cell lymphomas. Blood, 2008, 111, 2488-2489.	1.4	6
92	Genomic Analyses Reveal Global Functional Alterations That Promote Tumor Growth and Novel Tumor Suppressor Genes in Natural Killer-Cell Malignancies. Blood, 2008, 112, 3792-3792.	1.4	0
93	A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell, 2007, 129, 1401-1414.	28.9	3,390
94	MicroRNAs in Tumorigenesis. American Journal of Pathology, 2007, 171, 728-738.	3.8	200
95	Lack of A563G (I188V) missense mutation inRIZ/ PRDM2 in human diffuse large B-cell lymphomas. Genes Chromosomes and Cancer, 2007, 46, 416-418.	2.8	7
96	Quantitative Assessment of DNA Editing Enzymes in B-Cell Lymphomas.. Blood, 2007, 110, 4687-4687.	1.4	0
97	MicroRNA-Mediated Down-Regulation of the Tumor Suppressor Gene PRDM1/Blimp-1 in Diffuse Large B-Cell Lymphomas.. Blood, 2007, 110, 3187-3187.	1.4	0
98	Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood, 2006, 107, 4090-4100.	1.4	203
99	miR-155/BIC as an oncogenic microRNA. Genes Chromosomes and Cancer, 2006, 45, 211-212.	2.8	110
100	Neither Germinal Center (GC) vs Non-Germinal Center (Non-GC) Phenotype nor FOXP1 Expression Correlate with Outcome in AIDS-Associated Diffuse Large B-Cell Lymphoma (DLBCL): Study of Patients from AIDS Malignancies Consortium Trials 010 and 034.. Blood, 2006, 108, 2023-2023.	1.4	0
101	Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3627-3632.	7.1	1,295
102	Avian bic , a Gene Isolated from a Common Retroviral Site in Avian Leukosis Virus-Induced Lymphomas That Encodes a Noncoding RNA, Cooperates with c- myc in Lymphomagenesis and Erythroleukemogenesis. Journal of Virology, 2002, 76, 4275-4286.	3.4	152
103	Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene, 2001, 274, 157-167.	2.2	229